Decrease of Tyrosine Kinase Inhibitor in Patients with CML

Decrease of Tyrosine Kinase Inhibitor in Patients with CML

User Photo
ASHReport

3 years
4,952 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mhairi Copland, BSc (Hons) MB ChB PhD FRCP FRCPath of the University of Glasgow, presents a press briefing of Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study at the 58th ASH Annual Meeting in San Diego, CA.
Up Next Autoplay
>